JP2020512387A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512387A5
JP2020512387A5 JP2019554000A JP2019554000A JP2020512387A5 JP 2020512387 A5 JP2020512387 A5 JP 2020512387A5 JP 2019554000 A JP2019554000 A JP 2019554000A JP 2019554000 A JP2019554000 A JP 2019554000A JP 2020512387 A5 JP2020512387 A5 JP 2020512387A5
Authority
JP
Japan
Prior art keywords
substituted
group
salt
methoxy
halogen atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019554000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2018/014501 external-priority patent/WO2018182050A1/en
Publication of JP2020512387A publication Critical patent/JP2020512387A/ja
Publication of JP2020512387A5 publication Critical patent/JP2020512387A5/ja
Ceased legal-status Critical Current

Links

JP2019554000A 2017-03-31 2018-03-29 代謝性障害の治療の為の置換シクリル酢酸誘導体 Ceased JP2020512387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017072813 2017-03-31
JP2017072813 2017-03-31
PCT/JP2018/014501 WO2018182050A1 (en) 2017-03-31 2018-03-29 Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
JP2020512387A JP2020512387A (ja) 2020-04-23
JP2020512387A5 true JP2020512387A5 (https=) 2021-04-30

Family

ID=62116518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554000A Ceased JP2020512387A (ja) 2017-03-31 2018-03-29 代謝性障害の治療の為の置換シクリル酢酸誘導体

Country Status (10)

Country Link
US (1) US10968231B2 (https=)
EP (1) EP3601260A1 (https=)
JP (1) JP2020512387A (https=)
KR (1) KR20190136049A (https=)
CN (1) CN110678458A (https=)
AR (1) AR111199A1 (https=)
CA (1) CA3058588C (https=)
MX (1) MX2019011782A (https=)
TW (1) TW201841920A (https=)
WO (1) WO2018182050A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2018181847A1 (ja) 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US12516036B2 (en) 2019-05-31 2026-01-06 Hyundai Pharm Co., Ltd. Crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
TWI894280B (zh) * 2020-05-26 2025-08-21 南韓商愛思阿爾法數字醫療科技有限公司 用以治療癌症惡病質之系統、用以治療癌症惡病質之運算系統及其操作方法、以及非暫態電腦可讀取媒體
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN112830933A (zh) * 2021-02-04 2021-05-25 康化(上海)新药研发有限公司 一种3,4-二氢-2H-吡喃并[2,3-b]吡啶合成方法
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도
JPWO2023106310A1 (https=) * 2021-12-07 2023-06-15

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2002006234A1 (en) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Sulfone derivatives, process for their production and use thereof
NZ540381A (en) 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
AU2003284596A1 (en) 2002-11-22 2004-06-18 Takeda Pharmaceutical Company Limited Imidazole derivative, process for producing the same, and use
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JPWO2007013694A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 フェノキシアルカン酸化合物
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
KR20080033524A (ko) 2005-08-10 2008-04-16 다케다 야쿠힌 고교 가부시키가이샤 당뇨병 치료제
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2646430A1 (en) * 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
BRPI0713378A8 (pt) 2006-06-27 2018-01-02 Takeda Pharmaceutical composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto
EP2077267A4 (en) 2006-10-18 2010-04-07 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
US7652133B2 (en) 2006-10-19 2010-01-26 Takeda Pharmaceutical Company Limited Indole compound
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
EP2118066A1 (en) 2007-02-09 2009-11-18 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
CN102083783A (zh) 2007-10-10 2011-06-01 安姆根有限公司 取代的联苯gpr40调节剂
WO2009111056A1 (en) * 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
AU2011237775A1 (en) * 2010-04-06 2012-11-22 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US9181186B2 (en) 2012-02-13 2015-11-10 Takeda Pharmaceutical Company Limited Aromatic ring compound
PT3031799T (pt) 2013-08-09 2018-07-04 Takeda Pharmaceuticals Co Composto aromático
US9920040B2 (en) 2015-08-12 2018-03-20 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
US9908873B2 (en) 2015-08-12 2018-03-06 Janssen Pharmaceutica Nv GPR40 agonists for the treatment of type II diabetes
WO2017027312A1 (en) 2015-08-12 2017-02-16 Janssen Pharmaceutica Nv Gpr40 agonists for the treatment of type ii diabetes
JP6627397B2 (ja) 2015-10-09 2020-01-08 富士通オプティカルコンポーネンツ株式会社 光モジュール及び光伝送装置
WO2017172505A1 (en) 2016-03-29 2017-10-05 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2018081047A1 (en) 2016-10-25 2018-05-03 Janssen Pharmaceutica Nv Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
JPWO2018181847A1 (ja) * 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物

Similar Documents

Publication Publication Date Title
JP2020512387A5 (https=)
JP5985611B2 (ja) 炎症および免疫関連用途のための化合物
JP2009523146A5 (https=)
JP2008513515A5 (https=)
JP2016535772A5 (https=)
JP2018127459A5 (https=)
KR102212981B1 (ko) 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약
JP2005508967A5 (https=)
JP2014507464A5 (https=)
JP2013129675A5 (https=)
JP2017502940A5 (https=)
JP2016525130A5 (https=)
EP2948147A1 (en) N-substituted-5-substituted phthalamic acids as sortilin inhibitors
JP2004529161A5 (https=)
JP2011137006A5 (https=)
JP2016525075A5 (https=)
JP2005509003A5 (https=)
JP2008504304A5 (https=)
JP2020515620A5 (https=)
KR20210005668A (ko) Hpk1 억제제, 그의 제조 방법 및 응용
JP2007500719A5 (https=)
JP2010525023A5 (https=)
JP2006522035A5 (https=)
US7393959B2 (en) Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
JP2017538689A5 (https=)